Wendy McFalda, DO
Dermatology · Clarkston, MINPI 1528152196
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Pfizer at 37.1% of the total. Reporting peaked in 2021 at $28,725 and has fallen 50.8% since, to $14,131 in 2025. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,115 payments — averaging $69.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$29K
- Incyte Corporation$10K
- AbbVie$9K
- Eli Lilly$6K
- Lumenis BE Inc$2K
- Johnson & Johnson$2K
- plus $20K from 48 others
Across 688 payments — averaging $5401.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.6M
- UCB SA$661K
- Eli Lilly$578K
- Janssen Research & Development, LLC$165K
- Novartis$165K
- Sun Pharmaceutical Industries Inc.$130K
- plus $450K from 11 others
What the payments were for
- Consulting fees$20,20926%
- Speaking & faculty fees$28,86537%
- Travel & lodging$2,2893%
- Food & beverage$26,14634%
- Education$4681%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,977 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 40 | $286,260 |
| Taltz AutoinjectorIxekizumab | 24 | $161,903 |
| Humira(Cf) PenAdalimumab | 14 | $92,323 |
| Dupixent SyringeDupilumab | 23 | $89,470 |
| Dupixent PenDupilumab | 17 | $60,439 |
| Calcipotriene | 29 | $10,047 |
| Azelaic Acid | 38 | $5,679 |
| CiclopiroxCiclopirox Olamine | 50 | $2,847 |
| Tacrolimus | 51 | $2,631 |
| Fluorouracil | 37 | $1,827 |
| Ketoconazole | 102 | $1,507 |
| Clobetasol Propionate | 76 | $1,399 |
| Ciclopirox | 41 | $1,275 |
| Fluocinonide | 46 | $1,275 |
| Triamcinolone Acetonide | 117 | $869 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Clarkston
- Brett BenderClarkston$14K
- Michelle DawsonClarkston$13K
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.